• NEW! UVM Medical Center - Clinical Program Coordinator - Hematology 
• UVM Medical Center - CVMC - Medical Oncologist / Hematologist - general oncology and hematology (benign and malignant disease) and includes inpatient consult service and outpatient clinics 
• Northern Light Health - Physician Medical Director -Oncology Service Line
• UVM Cancer Center / Larner College of Medicine 
• Academic clinician with experience in lung cancer, melanoma and immunotherapy - Assistant or Associate Professor in the Clinical Scholars Pathway
• Physician-scientist/academic clinician with experience in breast cancer - Associate Professor or Full Professor in the Clinical Scholar Pathway
• Classical hematologist - Assistant Professor, Associate Professor, or Professor in the Clinical Scholar Pathway

Register for the series today and be sure to sign up for NNECOS sponsored lunch!

Learn more about our unique funding program! 

Join us in congratulating NAHPAC Special Award Recipients, Elizabeth McGrath and Nicole Messier! Saturday, September 10th, Nicole was recognized with a NAHPAC Distinguished Service Award, in recognition of her longstanding leadership as a co-chair of the committee, while Elizabeth was presented with a Founding Member Award, having served as a member of the committee since its founding in the fall of 2012. Thank you, Nicole and Elizabeth for your outstanding leadership and service to this important committee!

Please read this special message to our community.

Latest FDA Approvals

• November 18 - FDA approves a new dosing regimen for asparaginase erwinia chrysanthemi (recombinant)
• November 14 - FDA granted accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer
• November 10 - FDA approves tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancer
• November 10 - FDA approves brentuximab vedotin in combination with chemotherapy for pediatric patients with classical Hodgkin lymphoma
• November 8 - FDA approves cemiplimab-rwlc in combination with platinum-based chemotherapy for non-small cell lung cancer
• Oct 25 - FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma
• Oct 21 - FDA approves tremelimumab in combination with durvalumab for unresectable hepatocellular carcinoma

Other Updates

ASCO Survey on COVID in Oncology Registry

The aim is to help the cancer community learn more about the patterns of symptoms & severity of COVID among patients with cancer, as well as the impact on delivery of cancer care & patient outcomes. Periodic reports will deliver real-time information to the oncology community.

• ASCO Registry FAQs
• Enroll Your Practice
• Questions

ASCO COVID Resource Page

COVID Info & Resources including a Fact Sheet on EUA of BAmlanivimab